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Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) Coactivator-1 Alpha (PGC-1α)
is  involved  in  the  regulation  of  mitochondrial  biogenesis,  respiration  and  adaptive
thermogenesis. The full-length PGC-1α (FL-PGC-1α) comprises multiple functional domains
interacting with several transcriptional regulatory factors such as nuclear respiratory factors,
estrogen-related receptors and PPARs; however, a number of PGC-1α splice variants have
also been reported recently. In this study, we examined the expression levels of FL-PGC-1α
and N-truncated PGC-1α  (NT-PGC-1α), a shorter  but functionally active splice variant  of
PGC-1α protein, in N171-82Q transgenic and 3-nitropropionic acid-induced murine model of
Huntington’s disease (HD). The expression levels were determined by RT-PCR in three brain
areas (striatum, cortex and cerebellum) in three age groups (8, 12 and 16 weeks). Besides
recapitulating prior findings that NT-PGC-1α is preferentially increased in 16 weeks of age in
transgenic HD animals, we detected age-dependent alterations in both models, including a
cerebellum-predominant  upregulation  of  both  PGC-1α  variants  in  transgenic  mice,  and  a
striatum-predominant upregulation of both PGC-1α variants after acute 3-nitropropionic acid
intoxication.  The possible  relevance  of this  expression pattern is  discussed.  Based on our
results,  we  assume  that  increased  expression  of  PGC-1α  may  serve  as  a  compensatory
mechanism in  response  to  mitochondrial  damage  in  transgenic  and  toxin  models  of  HD,
which may be of therapeutic relevance.
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Introduction
Neurodegenerative  diseases  comprise  a  heterogeneous  group  of  neurological  disorders,
characterized  by  a  relatively  selective  damage  of  specific  regions  of  the  central  nervous
system. Mitochondrial  dysfunction has been implicated in the pathogenesis of all  of these
disorders, including Huntington’s disease . This is well underlined by the fact that there are
several mitochondrial toxins, including the irreversible complex II inhibitor 3-nitropropionic
acid (3-NP) for HD, which can be applied for the modelling of neuronal damage.
In  respect  of  the  major  regulators  of  mitochondrial  functioning,  Peroxisome
Proliferator-Activated Receptor-Gamma (PPARγ) Coactivator-1 Alpha (PGC-1α) is assumed
to  be  a  key  regulator  of  mitochondrial  biogenesis,  respiration,  energy  homeostasis  and
adaptive  thermogenesis  . The  human  PGC-1α  gene  (reference  gene)  is  located  on
chromosome 4p15.2  (chromosome 5  in  mice)  and encodes  a  full-length  protein  (FL-
PGC-1α) containing 798 (human) or 797 amino acid (mouse).
The PGC-1α protein has a complex structure with multiple domains, which enable the
interaction with several transcriptional regulatory factors, such as nuclear respiratory factors
(NRFs), estrogen-related receptors (ERRs) and PPARs . The N-terminal domain of the PGC-
1α protein mediates interactions with nuclear receptors (NRs) and regulates the transcriptional
activity, whereas the central and C-terminal domains mediate interactions with NRFs, PPARγ
and FOXO1 . The activation of NRFs leads to the elevated expression of nuclear-encoded
mitochondrial respiratory complex subunits and several mitochondrial factors, which control
the mitochondrial DNA transcription; furthermore, the PGC-1α able to regulate the fatty acid
oxidation via the induction of PPARγ . 
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Besides  the  FL-PGC-1α,  several  PGC-1α isoforms  have  been  presented  recently  .
Among  isoforms,  the  N-truncated  PGC-1α  (NT-PGC-1α)  is  a  major  one,  which  is
considerably shorter (267 amino acids) than FL-PGC-1α, but functionally active. NT-PGC-1α
develops via an alternative 3’ splicing between exons 6 and 7 that introduces an in-frame stop
codon  into  PGC-1α mRNA.  This  protein  retains  the  N-terminal  transcriptional  activation
domains but lacks all domains within 268-797 amino acid of the FL-PGC-1α . Beside these
two  major  isoforms,  novel  tissue-specific  PGC-1α isoforms  have  been  described
recently . 
The role of PGC-1α  system in neurodegenerative disorders including HD has been
reported both in human patients and in animal models . HD is an inherited neurodegenerative
disease caused by the expansion of CAG trinucleotide repeat that encodes the polyglutamine
region in the huntingtin protein. Transcriptional dysregulation, impaired energy metabolism
and increased oxidative stress have all been implicated in HD pathogenesis . In addition, the
interaction of mutant huntingtin with PGC-1α has been demonstrated in number of studies; in
particular, mutant huntingtin is able to disrupt proper mitochondrial functioning via inhibiting
the expression  and/or influencing the activity of PGC-1α protein . 
Accordingly, Chaturvedi et al. found significant reductions in the functioning of PGC-
1α and its downstream genes in myoblasts from the skeletal muscle of HD transgenic mice
and in muscle biopsy samples from HD patients . Previously,  Cui et al. demonstrated that
PGC-1α mRNA expression is significantly downregulated in HD striatal cells and tissues .
Furthermore, the reduction in PGC-1α mRNA level was demonstrated in post-mortem HD
brain tissues . All of these studies examined only the potential role of FL-PGC-1α expression
in HD. Johri  et  al.  were the first  to demonstrate  that  the expression level of NT-PGC-1α
protein is also altered in transgenic murine models of HD (including the N171-82Q transgenic
mice), as well as in human HD brain tissues and in a striatal HD cell line. They found that the
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NT-PGC-1α protein  is  depleted  in  human  HD myoblasts  and  mouse  Q111  striatal  cells.
Contrary, the level of this protein was decreased in human brains with early HD stages, but
was strongly increased in advanced stages of HD. Furthermore, they demonstrated that the
NT-PGC-1α protein was upregulated in the striatum of older N171-82Q and R6/2 HD mice
compared to younger animals, but  the NT-PGC-1α level was measured only in the striatum
and  not  in  other  brain  regions  . Although  the  PGC-1α  level  was  investigated  in  several
transgenic model of HD, there is no data about its mRNA levels in 3-NP induced HD mouse
model.
The aim of this study was to investigate the expression levels of FL-PGC-1α and NT-
PGC-1α in the striatum, cortex and the cerebellum of N171-82Q transgenic mice and in the
respective brain regions of the 3-NP-induced HD mice in three age groups. 
Materials and Methods
Animals
C57Bl/6 mice (8, 12 and 16 weeks old; male) and N171-82Q mice (8, 12 and 16 weeks old,
males and females equally distributed in each groups) were involved in this study. The latter
animal strain was originally obtained from Jackson Labs (Jackson Laboratories, USA).  The
symptoms of  N171-82Q mice  begin  to  develop at  8  weeks  of  age.  The gait  becomes
abnormal, tremor, hypokinesia and reduced locomotor activity evolve. The body weight
becomes progressively decreased, and the animals die at an average age of 110-120 days.
The animals were housed in cages under standard conditions with 12-12 h light-dark cycle
and free access to  food and water.  The experiments  were carried  out  in accordance  with
European  Communities  Council  Directive  (86/609/EEC)  and  were  approved  by the  local
animal care committee. 
Treatment and sample handling
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3-NP (Sigma Chemical, USA) was dissolved in phosphate-buffered saline (PBS; pH adjusted
to 7.4) and was administered intraperitoneally (i.p.) to male C57Bl/6 animals (the reason for
the exclusive application of male mice for 3-NP treatment was the fact that female mice are
considerably  resistant  to  toxin  treatment  with  a  relatively  large  variance).  Animals  of  a
particular age were randomly divided into four groups (n=6-7 in each group). The first group
received a single i.p. injection of 100 mg/kg body weight 3-NP (acute treatment), the second
one received 50 mg/kg body weight i.p. injection twice a day for 5 days (subacute treatment).
The third and fourth groups served as the respective control (ctrl) groups, and were injected
according to the above-detailed treatment regimen with the vehicle.
Ninety minutes after the last injection, the C57Bl/6 animals were deeply anesthetized with
isoflurane (Forane; Abott Laboratories Hungary Ltd., Budapest, Hungary) and immediately
perfused transcardially with artificial cerebrospinal fluid (composition in mM: 122 NaCl, 3
KCl, 1 Na2SO4, 1.25 KH2PO4, 10 D-glucose, 1 MgCl*6H2O, 2 CaCl2*2H2O, 6 NaHCO3) for 2
min with a flow rate of 10 ml/min by an automated peristaltic  perfusor. The brains were
rapidly removed on ice and immediately halved at the midline.  The right hemisphere was
dissected on ice, and the striatum, cortex and cerebellum were stored at -80 °C until the RT-
PCR analysis. The left hemisphere was postfixed in 4 w/v% paraformaldehyde overnight, and
then transmitted into glycerol  (10 v/v%) until  immunohistochemical  sample  processing in
case of subacute treatment regimen.
In case of transgenic (tg; n=6-7 in each group) N171-82Q mice and the corresponding wild-
type (wt; n=6-7 in each group) counterparts, both hemispheres were dissected into the proper
brain regions and were stored at -80 °C until the RT-PCR analysis.
RT-PCR analysis
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For RT-PCR analysis,  total  RNA was isolated from striatum, cortex and cerebellum with
Trizol according to the manufacturer’s protocol. RNA concentrations were determined using
MaestroNano  spectrophotometer,  and  the  integrity  of  RNA  was  confirmed  by  gel
electrophoresis using 1% agarose gel. cDNA was synthesized from 1 µg total RNA with
random  hexamer  primers  using  RevertAid  First  Strand  cDNA  Synthesis  Kit  (Thermo
Scientific, USA). cDNA were kept at -20 °C until further use.
Real-time  PCR was performed  on CFX 96 Real  Time  System (Bio-Rad,  USA) to detect
changes in mRNA expression, using various primer pairs at a final volume of 20 µl. Thermal
cycling conditions were 95 °C for 2 min, followed by 40 cycles of 95 °C for 10 s and 60 °C
for 30 s.  The relative mRNA level was calculated by the 2-∆∆Ct method . A pre-optimized
primer  and  probe  assay  for  18S  rRNA  was  used  as  an  endogenous  control  (Applied
Biosystems, USA).
Immunohistochemistry
After  postfixation  in  paraformaldehyde  and cryoprotection  in  glycerol,  30-µm-thick serial
sections were cut to obtain consecutive sections from the entire striatum. The sections were
collected into 12 wells consecutively, i.e. the distance between the studied sections was 360
µm. The free-floating sections were rinsed in PBS and transferred in methanol, containing 0.3
w/v% H2O2 for 30 min. After washing in PBS containing 1 v/v% Triton-X 100 (PBS-T) and
blocking  for  1  h  with  PBS-T containing  2  v/v% normal  horse  serum,  the  sections  were
incubated  for  one night  at  room temperature  in  PBS-T containing  the anti-NeuN primary
antibody at 1:10,000 dilution (Millipore,  USA). After rinsing in PBS-T, the sections were
incubated in biotinylated anti-mouse IgG for 2 h, followed by the application of avidin-biotin-
peroxidase  complex  in  PBS-T  for  2  h,  and  visualized  with  nickel  ammonium  sulphate-
intensified 3,3’-diaminobenzidine (Sigma-Aldrich, USA). The sections were dried overnight
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on  glass  slides,  and  coverslipped  using  DPX  as  mounting  medium.  The  sections  were
analysed  in  a  Zeiss  Axio  Imager  M2  Upright  Microscope  (Carl  Zeiss  MicroImaging,
Germany)  supplied  with  an  AxioCam  MRC  camera.  Photographs  were  taken  at  10x
magnification. For the determination of NeuN density in the striatum, the MosaiX program
feature of  AxioVision program was used.  Briefly,  we measured  the density  of the whole
striatum and the corresponding corpus callosum in the consecutive sections and substracted
the values from each other to normalize the method for probable different background stain.
After adjusting the differences for the parameters of the corresponding striatum, we calculated
the average density/mm2 values. Thereafter, we compared these derived values in ctrl and 3-
NP-treated animals.
Statistics
All statistical  analyses were performed with the SPSS Statistics 17.0 software (SPSS Inc.,
USA). The normality of data  was checked by Shapiro-Wilk W test.  As most  of our data
groups  showed  non-Gaussian  distribution  and/or  displayed  significant  difference  in  the
homogeneity of variance (checked with the Levene’s test), we used non-parametric statistics
(Mann-Whitney  U  test)  for  the  comparison  of  the  relative  levels  of  expression  between
groups.  Due  to  multiple  comparisons,  in  cases  of  either  FL-PGC-1α or  NT-PGC-1α the
necessary corrections were done on p values. After corrections, a p < 0.05 value was regarded
as significant. We calculated the level of gene expression of all brain areas in all age groups
relative to the level of FL-PGC-1α gene expression in 8-week-old wt/ctrl striatum. The data
were plotted and expressed as median and interquartile range. 
Since  the  data  obtained  from  the  quantitative  analysis  of  immunohistochemical
patterns showed Gaussian distribution, we used the independent  t  test for the comparison of




There were no detectable changes in the FL-PGC-1α or NT-PGC-1α levels of wt animals with
aging.  Furthermore,  we could  not  detect  differences  in  PGC-1α levels  between male  and
female mice in tg/wt groups. The NT-PGC-1α expression level was approximately 30% of the
mRNA level  of FL-PGC-1α in all  brain regions of  wt animals.  Our results  demonstrated
significantly reduced FL-PGC-1α expression in the striatum (0.59 (0.50–0.77); p=0.039) and
cortex  (0.83;  (0.56–0.90);  p=0.009)  of  8-week-old  tg  mice compared  to  the  values  of  wt
animals  (striatum:  0.96  (0.77–1.29);  cortex:  1.49  (1.33–1.77)),  but  we  could  not  detect
significant changes in these brain regions of older mice (Fig. 1.A, C). The FL-PGC-1α mRNA
showed a tendency to  increase  in  the  cerebellum of  8-week-old tg  mice  compared to  wt
animals, which changes became significant in 12-week-old (wt: 0.23 (0.20–0.30); tg: 0.82;
(0.58–0.89); p=0.004) and 16-week-old tg mice (wt: 0.22 (0.15–0.27); tg: 0.74 (0.68–0.82);
p=0.018,  Fig.  1.E).  NT-PGC-1α  expression  showed  a  mild  tendency  of  decrease  in  the
striatum and cortex of 8-week-old tg mice, but it was significantly upregulated in the striatum
(wt: 0.25 (0.23–0.33); tg: 0.76 (0.53–0.86); p=0.018)  and cortex of 16-week-old tg animals
(wt: 0.45 (0.30–0.52); tg: 1.15 (0.89–1.33); p=0.018, Fig. 1.B, D). In the cerebellum, NT-
PGC-1α expression was, however, significantly increased as early as 8 weeks of age in tg
mice (0.18 (0.17–0.24); p=0.009) compared to wt animals (0.07 (0.07–0.13)). This difference
also  remained  significant  in  12-week-old  (wt:  0.06  (0.05–0.09);  tg:  0.37  (0.25–0.49);




After a single injection of 3-NP, the FL-PGC-1α expression had a tendency to be increased in
the striatum and cortex of all three age groups of C57Bl/6 mice,  which reached statistical
significance in the striatum of 16-week-old animals (ctrl: 1.04 (0.89-1.09); 3-NP: 1.37 (1.20-
1.76); p=0.036) and in the cortex of 12-week-old animals (ctrl: 1.10 (0.84-1.27); 3-NP: 1.67
(1.60-1.84); p=0.018) (Fig. 2.A, C), but not in other age groups. Contrarily, the alterations in
the  NT-PGC-1α  expression  were  significant  only  in  the  striatum  (Fig.  2.B),  where  its
expression was significantly greater in 3-NP-treated mice at 12 weeks of age (ctrl: 0.32 (0.26-
0.37); 3-NP: 0.62 (0.57-0.76); p=0.018) and 16 weeks of age (ctrl: 0.39 (0.36-0.41); 3-NP:
0.55 (0.51-0.65); p=0.036) compared to the respective ctrl animals.
We did not find differences in FL-PGC-1α and NT-PGC-1α levels in the cerebellum in either
group (Fig. 2.E, F).
Subacute 3-NP treatment
The subacute 3-NP regimen resulted in a significant reduction (28%, ctrl: 3414.9 ± 157.4; 3-
NP: 2443 ± 339.8; p=0.04) in the NeuN-related density values in the striatum of 3-NP-treated
mice  compared  to  ctrl  animals,  representing  the  toxin-induced  neuronal  damage
(Supplementary Fig. 1). After subacute 3-NP treatment,  however, no changes in the FL-
PGC-1α or NT-PGC-1α levels were demonstrated between ctrl and 3-NP-treated animals in
any brain area of any age group. (Fig. 3.A-F).
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Discussion
Although it  is  known that  an abnormal  trinucleotide  repeat  expansion leads  to  the
development of HD, the precise pathomechanism is still not fully understood. 
The use of transgenic murine models of HD enables to get a better insight into the
pathomechanism of  the  disease. The  pathogenic  process  shows  progression  in  transgenic
murine  models,  including  the  N171-82Q  strain.  However,  there  are  some  age-dependent
adaptive processes which may serve as protective tools to ameliorate the disease progression .
Jarabek et al. observed that N171-82Q mice adapt to NMDA receptor-mediated excitotoxicity
in  an  age-dependent  manner,  and  the  authors  concluded  that  N171-82Q mice  attempt  to
compensate for the progression of HD .
The involvement of mitochondrial dysfunction and the role of PGC-1α, which is a key
regulator of mitochondrial biogenesis and antioxidant response, have been demonstrated in
the pathogenesis of HD . In particular, alterations in the expression of FL- and NT-PGC-
1α protein in HD are the most well established . Notably, novel tissue-specific isoforms
transcribed from an alternative upstream promoter have also been described recently in
humans  ;  the  altered  expression of  which,  however,  have not  yet  been described  in
neurodegenerative diseases.
Supporting the  role  of  PGC-1α gene  in  HD,  it  has  also  been implicated as  a
candidate modifier gene in HD; indeed, a number of variations demonstrated modifying
effects on the age at onset (AO) . Among them, the  rs7665116 polymorphism has been
proven  to  have  significant  association  with  AO,  i.e.  its  presence  was  related  to  a
protective  effect  in  three  European  HD cohorts  .  However,  Ramus et  al.  could  not
confirm these results , which contradiction may be explained by the difference in the
genetic  backgrounds  of  the  different  populations  examined.  Furthermore,  certain
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haplotypes of a haplotype block where the promoter of novel PGC-1α isoforms is located
have also shown association with AO in HD .
In this study, we aimed to demonstrate the age- and brain region-related changes in the
mRNA expression of  FL-PGC-1α and one of its  main  splice  variants,  NT-PGC-1α,  in  a
transgenic  and  a  toxin-induced  murine  model  of  HD.  Alterations  of  these  two  main
isoforms  have  only  been  demonstrated  in  transgenic  HD  mice  at  the  protein  level,
whereas the role of PGC-1α system in 3-NP model of HD has not yet been addressed. 
Recent  studies  reported  male-specific  roles  of  PGC-1α  in  neurodegenerative
disorders . Notably, however, in our experiments, we could not detect any difference in
PGC-1α levels between genders either in N171-82Q tg mice or their wt counterparts,
therefore we were able to use pooled data in this case for further analyses. 
In the N171-82Q transgenic mouse model, we measured reduced FL-PGC-1α mRNA
levels in the striatum (the most affected region in HD) and the overlying cortex of 8-week-old
tg mice, which difference became normalized in older HD mice. This could represent an age-
dependent compensatory mechanism against the well-documented mitochondrial dysfunction
in this transgenic mouse model of HD . However, we could not detect a difference in FL-
PGC-1α mRNA expression between 8-week-old wt and tg mice in the cerebellum, which is
known to be a relatively resistant region to the degenerative changes in HD . Interestingly,
however,  in  older  animals  the  expression  level  of  FL-PGC-1α  mRNA in  the  cerebellum
showed a remarkable increase. Considering the possible neuroprotective roles of PGC-1α in
HD  ,  this  cerebellum-predominant  potentially  compensatory  phenomenon  against
mitochondrial dysfunction-related energy deficit might be an important factor underlying the
relative  resistance  of  cerebellar  neurons  against  neurodegenerative  processes  in  HD.  This
would be in line with the finding of reactive astrogliosis indicative of neuronal degeneration
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in the cerebellar nuclei of FL-PGC-1α knockout mice, which is virtually absent in the striatum
and the cortex of these animals .
Although the FL form of PGC-1α is the major gene product, the NT-PGC-1α splice
variant  could  also  have  important  functions  in  terms  of  neurodegeneration.  The  PGC-1α
protein has a complex structure with multiple functional domains. The N-terminal domain of
the PGC-1α protein mediates interactions with nuclear receptors, regulates a proportion of the
PGC-1α-mediated  transcriptional  activity  and  contains  a  strong  activation  domain  .
Accordingly, the role of NT-PGC-1α has also been studied in HD pathogenesis . Johri et al.
found that NT-PGC-1α protein was upregulated in the striatum of 4-month-old N171-82Q HD
mice (and in 3-month-old R6/2 strain mice). They also studied the FL-PGC-1α level in the
striatum and  not  in  other  brain  regions.  In  addition  to  the  detection  of  a  rather  similar
elevation in NT-PGC-1α expression in the striatum of 16-week-old tg mice at the mRNA
level as Johri et al. observed at the protein level, we also observed this type of change in the
overlying  cortex.  Furthermore,  we detected  a  considerable  elevation  of  cerebellar  mRNA
expression  of  NT-PGC-1α  as  well,  in  a  very  similar  pattern  to  that  of  FL-PGC-1α.  The
background of this preferential increased expression of the NT variant is currently unknown;
however,  it  might  represent  an  important  shift  in  the  transcriptional  regulation  of
mitochondrial functions in HD, and implicate the potential role of the N-terminal domain-
regulated nuclear  receptors,  especially the known neuroprotective PPARs , as endogenous
compensatory mechanisms in HD.
Although the transgenic models have several undisputable advantages, the simplicity of the
application of mitochondrial toxin models of HD provide a rapid assessment tool, e.g. for the
screening  of  drug  effects.  Accordingly,  the  mitochondrial  toxin  3-NP  has  been  well
characterized as an experimental model of HD . This toxin inhibits mitochondrial complex II,
inducing a mitochondrial  dysfunction  which causes striatal  lesion .  A number of  studies
13
demonstrated that female animals are considerably resistant to 3-NP toxin treatment .
Since the mechanism of this differential effect of the toxin is not fully understood, it
would be hard to distinguish if any difference between genders were due to CNS-specific
mechanisms or merely due to secondary effects of differential pharmacokinetics of the
toxin. Accordingly, since our aim was to examine the evoked effect of the toxin per se on
expression patterns, we considered female mice inapplicable for animal modelling of HD
in 3-NP experiments,  and only  male mice were involved.  We measured the PGC-1α
expression  levels  either  after  a  single  injection  of  3-NP or  after  its  application  in  a
subacute dosing regimen.
After a single injection of 3-NP, the FL-PGC-1α expression was consistently increased in all
three age groups in the striatum and cortex; however, it reached significance only in older
animals after strict statistical correction. On the other hand, the NT-PGC-1α expression was
increased significantly only in the striatum of older 3-NP-treated mice. We propose that this
acute elevation after a single mitochondrial stress event might be an important compensatory
response to acute energy deficit and/or oxidative stress due to 3-NP-induced mitochondrial
dysfunction. In  addition,  the  predominant  elevation  in  aged animals  may reflect  the  age-
dependent vulnerability of the striatum to oxidative stress due to 3-NP treatment , as a more
pronounced toxicity  might  evoke a  more  expressed  compensatory  response.  Interestingly,
however, we did not find any difference in the expression levels of PGC-1α in the cerebellum
of either  age group, which might  be underlied by the fact  that 3-NP is  a rather  selective
striatal neurotoxin, and only limited cell death and energy deficit is observed in other brain
regions .
Surprisingly, there were no differences in either the FL-PGC-1α or the NT-PGC-1α
mRNA levels between toxin-treated and control animals in the striatum (nor in other brain
regions) at any age group after subacute 3-NP treatment (a total of 10 injections within 5
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days). We suggest that this may be the result of a reduced neuronal adaptive capability of the
striatum due to the histologically verified neuronal damage.
Although 3-NP model is one of the most widely applied toxin model of HD, this
model  cannot mimic all  alterations  of  genetically  determined HD. Indeed,  3-NP is  a
mitochondrial toxin which inhibits complex II and causes preferential striatal cell death,
whereas in the transgenic model other brain regions are affected as well. We believe that
the findings that NT-PGC-1α expression is elevated only in the striatum but not in other
brain regions in the acute 3-NP model may represent this preferential effect of 3-NP in
comparison with the transgenic model.
Supported by the prior findings that PGC-1α-deficient neurons  have increased
sensitivity to mitochondrial toxicity  , our results suggest that upregulation of PGC-1α
system may represent and important compensatory mechanism against mitochondrial
dysfunction in HD. 
Conclusions
To our knowledge this is the first report on the alterations in the expression profile of the main
PGC-1α splice  variants  at  the  mRNA level  in  multiple  brain  regions  of  different  murine
models of HD. Besides recapitulating the prior findings of Johri et al. that NT-PGC-1α at the
protein level is increased in 16 weeks of age in transgenic HD animals,  we detected age-
dependent  alterations  in  the  PGC-1α expression pattern  that  may correspond with known
predilections  of neurodegeneration in HD. Based on our results,  we suggest that  elevated
expression of  PGC-1α could be an important  tool  for  the  compensation  of  mitochondrial
damage in both transgenic and toxin models of HD. Although it is of question whether this
mechanism alone would be enough to ameliorate the neurodegenerative process, it may surely
serve as an important target for drug development in this currently incurable disease.
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Fig. 1 Relative mRNA expression of FL-PGC-1α and NT-PGC-1α in the striatum, cortex and
the cerebellum of N171-82Q transgenic and respective wild-type mice in three age groups.
The  FL-PGC-1α  was  significantly  reduced  in  8-week-old  tg  striatum  and  cortex  (A,  C
respectively). In the cerebellum, FL-PGC-1α mRNA was significantly increased in 12-week-
old  and  16-week-old  tg  mice  (E).  The  NT-PGC-1α  was  significantly  upregulated  in  the
striatum and cortex of 16-week-old animals (B, D respectively). The NT-PGC-1α expression
was increased in all three age groups in the cerebellum (F). Values are plotted as medians and
interquartile range; *p<0.05, **p<0.01; tg transgenic, wt wild-type, w weeks.
Fig. 2 FL-PGC-1α and NT-PGC-1α levels in the striatum, cortex and the cerebellum in three
age  groups  of  mice  following  acute  3-NP  intoxication.  The  FL-PGC-1α  expression  was
significantly increased in the striatum of 16-week-old 3-NP treated mice and in the cortex of
12-week-old  3-NP treated  mice  (A,  C  respectively).  The  FL-PGC-1α  expression  did  not
change in the cerebellum of 3-NP treated mice (E). The NT-PGC-1α mRNA was significantly
upregulated in the 12-week-old and 16-week-old 3-NP treated mice striatum (B). In the cortex
and cerebellum of 3-NP treated mice there were no differences in the NT-PGC-1α mRNA
levels (D, F respectively). Values are plotted as medians and interquartile range; *p<0.05; ctrl
control, 3-NP 3-NP-treated, w weeks.
Fig. 3 Analysis of relative FL-PGC-1α and NT-PGC-1α mRNA expression of subacute 3-NP-
treated mice in three age groups. We measured the FL-PGC-1α level in the striatum (A),
cortex (C) and cerebellum (E) and the NT-PGC-1α levels in the striatum (B), cortex (D) and
cerebellum (F),  but  we could  not  detect  differences  between  ctrl  and 3-NP-treated  mice.
Values are  plotted  as  medians  and interquartile  range;  ctrl  control,  3-NP  3-NP-treated,  w
weeks.
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